Trial · NCT03277352
Adverse events108
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 108
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Headache | Nervous system disorders | Total | 1 | 10 | 1 |
| other | Herpes zoster | Infections and infestations | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Herpes zoster | Infections and infestations | Total | 1 | 10 | 1 |
| other | Hydrogen breath test abnormal | Investigations | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Hydrogen breath test abnormal | Investigations | Total | 1 | 10 | 1 |
| other | Hyperchloraemia | Metabolism and nutrition disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Hyperchloraemia | Metabolism and nutrition disorders | Total | 1 | 10 | 1 |
| other | Hyperuricaemia | Metabolism and nutrition disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Hyperuricaemia | Metabolism and nutrition disorders | Total | 1 | 10 | 1 |
| other | Hypomagnesaemia | Metabolism and nutrition disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 2 | 10 | 2 |
| other | Hypomagnesaemia | Metabolism and nutrition disorders | Total | 2 | 10 | 2 |
| other | Lipase increased | Investigations | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 2 | 10 | 2 |
| other | Lipase increased | Investigations | Total | 2 | 10 | 2 |
| other | Lung infiltration | Respiratory, thoracic and mediastinal disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Lung infiltration | Respiratory, thoracic and mediastinal disorders | Total | 1 | 10 | 1 |
| other | Macular hole | Eye disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Macular hole | Eye disorders | Total | 1 | 10 | 1 |
| other | Melaena | Gastrointestinal disorders | INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID | 1 | 10 | 1 |
| other | Melaena | Gastrointestinal disorders | Total | 1 | 10 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03277352/events?page=3